KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Globus Medical (GMED) Share-based Compensation (2016 - 2025)

Globus Medical (GMED) has disclosed Share-based Compensation for 15 consecutive years, with $11.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 4.11% year-over-year to $11.4 million, compared with a TTM value of $49.8 million through Dec 2025, down 8.14%, and an annual FY2025 reading of $49.8 million, down 8.14% over the prior year.
  • Share-based Compensation was $11.4 million for Q4 2025 at Globus Medical, down from $11.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $22.8 million in Q3 2023 and bottomed at $7.5 million in Q3 2021.
  • Average Share-based Compensation over 5 years is $11.0 million, with a median of $10.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation surged 173.69% in 2023, then plummeted 46.34% in 2024.
  • Year by year, Share-based Compensation stood at $7.8 million in 2021, then increased by 8.99% to $8.5 million in 2022, then skyrocketed by 46.29% to $12.4 million in 2023, then dropped by 4.32% to $11.9 million in 2024, then dropped by 4.11% to $11.4 million in 2025.
  • Business Quant data shows Share-based Compensation for GMED at $11.4 million in Q4 2025, $11.5 million in Q3 2025, and $13.6 million in Q2 2025.